Get the latest news, insights, and market updates on PHAT (Phathom Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks
As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed a simple script. Policy uncertainty lingered, and trade headlines remained unpredictable as President Trump continued to keep markets guessing. And yet, corporate earnings held up and equities proved surprisingly resilient. That staying power is exactly what stood out to Raymond James Chief Investment Officer Larry Adam, who sees 2025 as a reminder of how adaptable markets Dec 26, 2025 - $PHAT
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals’ Long-Term Strategy (PHAT)?
Phathom Pharmaceuticals recently announced that it has dosed the first patient in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA tablets for eosinophilic esophagitis (EoE) in adults, with topline results expected in 2027. This clinical milestone reflects the company’s efforts to expand VOQUEZNA’s potential indications and address unmet needs in gastrointestinal disorders. We’ll now explore how progress in clinical development for VOQUEZNA could shape Phathom Pharmaceuticals’ broader... Nov 13, 2025 - $PHAT
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA Nov 4, 2025 - $PHAT
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MADate: Monday, November 10, 2025Live Webcast: 3:00 pm ESTManagement to Nov 3, 2025 - $PHAT
Phathom Pharmaceuticals (PHAT): Forecasts Call for 75% Annual Earnings Growth as Losses Deepen
Phathom Pharmaceuticals (PHAT) remains unprofitable, with annual losses accelerating at a rate of 20.8% over the past five years. The company is expected to see earnings grow by 74.96% annually and to reach profitability within three years, with revenue projected to expand 34.3% per year, significantly above the broader US market’s 10.3% forecast. These growth expectations must be balanced against the unbroken streak of losses and concerns about financial health as investors weigh both risk... Oct 31, 2025 - $PHAT
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceutic Oct 30, 2025 - $PHAT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple